[시장보고서]저분자 이노베이터 API CDMO 시장 : 산업 분석, 규모, 점유율, 성장, 동향, 예측(2024-2032년)

저분자 이노베이터 API CDMO 시장 : 산업 분석, 규모, 점유율, 성장, 동향, 예측(2024-2032년)

Global Small Molecule Innovator API CDMO Market Research Report - Industry Analysis, Size, Share, Growth, Trends and Forecast 2024 to 2032

상품코드 : 1469845

리서치사 : Value Market Research

발행일 : 2024년 04월

페이지 정보 : 영문 172 Pages

라이선스 & 가격 (부가세 별도)

US $ 3,920

￦ 5,816,000

PDF & Excel (Single User License)

PDF 및 Excel 보고서를 1명만 이용할 수 있는 라이선스입니다. 텍스트의 Copy & Paste 가능합니다. 인쇄 가능하며 인쇄물의 이용 범위는 전자파일의 이용 범위와 동일합니다.

US $ 4,730

￦ 7,017,000

PDF & Excel (10-user License)

PDF 및 Excel 보고서를 동일 기업 내 10명까지 이용할 수 있는 라이선스입니다. 텍스트의 Copy & Paste 가능합니다. 인쇄 가능하며 인쇄물의 이용 범위는 전자파일의 이용 범위와 동일합니다.

US $ 7,430

￦ 11,023,000

PDF & Excel (Corporate User License)

PDF 및 Excel 보고서를 동일 기업 내 모든 사용자가 이용할 수 있는 라이선스입니다. 텍스트의 Copy & Paste 가능합니다. 인쇄 가능하며 인쇄물의 이용 범위는 전자파일의 이용 범위와 동일합니다.

ㅁ Add-on 가능: 고객의 요청에 따라 일정한 범위 내에서 Customization이 가능합니다. 자세한 사항은 문의해 주시기 바랍니다.

한글목차

샘플 요청 목록에 추가

세계의 저분자 이노베이터 API CDMO 시장 규모는 2023년에 301억 6,000만 달러에 달하며, 2024-2032년의 예측 기간 중 CAGR 7.41%로 성장하며, 2032년에는 약 573억 9,000만 달러에 달할 것으로 예측되고 있습니다.

이 조사 리포트는 Porter's Five Forces 모델, 시장의 매력 분석, 밸류체인 분석을 다루고 있습니다. 이 툴은 산업의 구조를 명확하게 파악하고, 세계 레벨에서의 경쟁 매력을 평가하는데 도움이 됩니다. 또한 이 툴은 세계의 저분자 이노베이터 API CDMO 시장에서 각 부문을 종합적으로 평가할 수도 있습니다. 저분자 이노베이터 API CDMO 산업의 성장과 동향은 이 조사에 전체적인 어프로치를 제공합니다.

시장 세분화

본 섹션에서는 저분자 이노베이터 API CDMO 시장 보고서의 국가별·지역별 부문에 관한 상세 데이터를 제공하고, 전략가가 향후 비즈니스 기회와 함께 각 제품·서비스의 타깃층을 식별하는데 도움이 됩니다.

스테이지 유형별

전임상
임상
상업

고객 유형별

제약
바이오테크놀러지

치료 영역별

순환기 질환
종양
호흡기질환
신경
대사질환
감염증
기타

지역 분석

이 섹션에서는 북미, 유럽, 아시아태평양, 라틴아메리카, 중동 및 아프리카에서 저분자 이노베이터 API CDMO 시장의 현재와 향후 수요를 강조하는 지역 전망을 다루고 있습니다. 또한 유명 전 지역에서 개별 용도 부문의 수요·추정·예측에 초점을 맞추고 있습니다.

전망 : 지역별
서론
북미 판매 분석
- 개요, 실적과 예측
- 북미 : 부문별
- 북미 : 국가별
- 미국
- 캐나다
- 멕시코
유럽 판매 분석
- 개요, 실적과 예측
- 유럽 : 부문별
- 유럽 : 국가별
- 영국
- 프랑스
- 독일
- 이탈리아
- 러시아
- 기타 유럽
아시아태평양 판매 분석
- 개요, 실적과 예측
- 아시아태평양 : 부문별
- 아시아태평양 : 국가별
- 중국
- 인도
- 일본
- 한국
- 호주
- 동남아시아
- 기타 아시아태평양
라틴아메리카 판매 분석
- 개요, 실적과 예측
- 라틴아메리카 : 부문별
- 라틴아메리카 : 국가별
- 브라질
- 아르헨티나
- 페루
- 칠레
- 기타 라틴아메리카
중동 및 아프리카 판매 분석
- 개요, 실적과 예측
- 중동 및 아프리카 : 부문별
- 중동 및 아프리카 : 국가별
- 사우디아라비아
- 아랍에미리트
- 이스라엘
- 남아프리카공화국
- 기타 중동 및 아프리카

제9장 저분자 이노베이터 API CDMO 기업의 경쟁 구도

저분자 이노베이터 API CDMO 시장 경쟁
파트너십/제휴/합의
합병·인수
신제품 출시
기타 개발

제10장 기업 개요

상위 기업의 시장 점유율 분석
시장 집중도
Lonza Group Ltd.
Novo Holdings(Catalent Inc.)
Thermo Fisher Scientific Inc.
Siegfried Holding AG
Recipharm AB
CordenPharma International
Samsung Biologics
LabCorp
Ajinomoto Bio-Pharma Services
Piramal Pharma Solutions
Jubilant Life Sciences(Jubilant Biosys Ltd.)
WuXi AppTec Co. Ltd.

KSA

영문 목차

영문목차

The global demand for Small Molecule Innovator API CDMO Market is presumed to reach the market size of nearly USD 57.39 Billion by 2032 from USD 30.16 Billion in 2023 with a CAGR of 7.41% under the study period 2024 - 2032.

The research report covers Porter's Five Forces Model, Market Attractiveness Analysis, and Value Chain analysis. These tools help to get a clear picture of the industry's structure and evaluate the competition attractiveness at a global level. Additionally, these tools also give an inclusive assessment of each segment in the global market of small molecule innovator api cdmo. The growth and trends of small molecule innovator api cdmo industry provide a holistic approach to this study.

MARKET SEGMENTATION

This section of the small molecule innovator api cdmo market report provides detailed data on the segments at country and regional level, thereby assisting the strategist in identifying the target demographics for the respective product or services with the upcoming opportunities.

By Stage Type

Preclinical
Clinical (Phase I, Phase II, Phase III)
Commercial

By Customer Type

Pharmaceutical (Small, Medium, Large)
Biotechnology (Small, Medium, Large)

By Therapeutic Area

Cardiovascular Diseases
Oncology
Respiratory Disorders
Neurology
Metabolic Disorders
Infectious Diseases
Others

REGIONAL ANALYSIS

This section covers the regional outlook, which accentuates current and future demand for the Small Molecule Innovator API CDMO market across North America, Europe, Asia-Pacific, Latin America, and Middle East & Africa. Further, the report focuses on demand, estimation, and forecast for individual application segments across all the prominent regions.

The research report also covers the comprehensive profiles of the key players in the market and an in-depth view of the competitive landscape worldwide. The major players in the Small Molecule Innovator API CDMO market include Lonza Group Ltd., Novo Holdings (Catalent Inc.), Thermo Fisher Scientific, Inc., Siegfried Holding AG, Recipharm AB, CordenPharma International, Samsung Biologics, LabCorp, Ajinomoto Bio-Pharma Services, Piramal Pharma Solutions, Jubilant Life Sciences (Jubilant Biosys Ltd.), WuXi AppTec Co., Ltd. This section consists of a holistic view of the competitive landscape that includes various strategic developments such as key mergers & acquisitions, future capacities, partnerships, financial overviews, collaborations, new product developments, new product launches, and other developments.

In case you have any custom requirements, do write to us. Our research team can offer a customized report as per your need.

1. PREFACE

1.1. Report Description
- 1.1.1 Objective
- 1.1.2 Target Audience
- 1.1.3 Unique Selling Proposition (USP) & offerings
1.2. Research Scope
1.3. Research Methodology
- 1.3.1 Market Research Process
- 1.3.2 Market Research Methodology

2. EXECUTIVE SUMMARY

2.1. Highlights of Market
2.2. Global Market Snapshot

3. SMALL MOLECULE INNOVATOR API CDMO - INDUSTRY ANALYSIS

3.1. Introduction - Market Dynamics
3.2. Market Drivers
3.3. Market Restraints
3.4. Opportunities
3.5. Industry Trends
3.6. Porter's Five Force Analysis
3.7. Market Attractiveness Analysis
- 3.7.1 Market Attractiveness Analysis By Stage Type
- 3.7.2 Market Attractiveness Analysis By Customer Type
- 3.7.3 Market Attractiveness Analysis By Therapeutic Area
- 3.7.4 Market Attractiveness Analysis By Region

4. VALUE CHAIN ANALYSIS

4.1. Value Chain Analysis
4.2. Raw Material Analysis
- 4.2.1 List of Raw Materials
- 4.2.2 Raw Material Manufactures List
- 4.2.3 Price Trend of Key Raw Materials
4.3. List of Potential Buyers
4.4. Marketing Channel
- 4.4.1 Direct Marketing
- 4.4.2 Indirect Marketing
- 4.4.3 Marketing Channel Development Trend

5. GLOBAL SMALL MOLECULE INNOVATOR API CDMO MARKET ANALYSIS BY STAGE TYPE

5.1. Overview By Stage Type
5.2. Historical and Forecast Data
5.3. Analysis By Stage Type
5.4. Preclinical Historic and Forecast Sales By Regions
5.5. Clinical (Phase I, Phase II, Phase III) Historic and Forecast Sales By Regions
5.6. Commercial Historic and Forecast Sales By Regions

6. GLOBAL SMALL MOLECULE INNOVATOR API CDMO MARKET ANALYSIS BY CUSTOMER TYPE

6.1. Overview By Customer Type
6.2. Historical and Forecast Data
6.3. Analysis By Customer Type
6.4. Pharmaceutical (Small, Medium, Large) Historic and Forecast Sales By Regions
6.5. Biotechnology (Small, Medium, Large) Historic and Forecast Sales By Regions

7. GLOBAL SMALL MOLECULE INNOVATOR API CDMO MARKET ANALYSIS BY THERAPEUTIC AREA

7.1. Overview By Therapeutic Area
7.2. Historical and Forecast Data
7.3. Analysis By Therapeutic Area
7.4. Cardiovascular Diseases Historic and Forecast Sales By Regions
7.5. Oncology Historic and Forecast Sales By Regions
7.6. Respiratory Disorders Historic and Forecast Sales By Regions
7.7. Neurology Historic and Forecast Sales By Regions
7.8. Metabolic Disorders Historic and Forecast Sales By Regions
7.9. Infectious Diseases Historic and Forecast Sales By Regions
7.10. Others Historic and Forecast Sales By Regions

8. GLOBAL SMALL MOLECULE INNOVATOR API CDMO MARKET ANALYSIS BY GEOGRAPHY

8.1. Regional Outlook
8.2. Introduction
8.3. North America Sales Analysis
- 8.3.1 Overview, Historic and Forecast Data Sales Analysis
- 8.3.2 North America By Segment Sales Analysis
- 8.3.3 North America By Country Sales Analysis
- 8.3.4 United States Sales Analysis
- 8.3.5 Canada Sales Analysis
- 8.3.6 Mexico Sales Analysis
8.4. Europe Sales Analysis
- 8.4.1 Overview, Historic and Forecast Data Sales Analysis
- 8.4.2 Europe By Segment Sales Analysis
- 8.4.3 Europe By Country Sales Analysis
- 8.4.4 United Kingdom Sales Analysis
- 8.4.5 France Sales Analysis
- 8.4.6 Germany Sales Analysis
- 8.4.7 Italy Sales Analysis
- 8.4.8 Russia Sales Analysis
- 8.4.9 Rest Of Europe Sales Analysis
8.5. Asia Pacific Sales Analysis
- 8.5.1 Overview, Historic and Forecast Data Sales Analysis
- 8.5.2 Asia Pacific By Segment Sales Analysis
- 8.5.3 Asia Pacific By Country Sales Analysis
- 8.5.4 China Sales Analysis
- 8.5.5 India Sales Analysis
- 8.5.6 Japan Sales Analysis
- 8.5.7 South Korea Sales Analysis
- 8.5.8 Australia Sales Analysis
- 8.5.9 South East Asia Sales Analysis
- 8.5.10 Rest Of Asia Pacific Sales Analysis
8.6. Latin America Sales Analysis
- 8.6.1 Overview, Historic and Forecast Data Sales Analysis
- 8.6.2 Latin America By Segment Sales Analysis
- 8.6.3 Latin America By Country Sales Analysis
- 8.6.4 Brazil Sales Analysis
- 8.6.5 Argentina Sales Analysis
- 8.6.6 Peru Sales Analysis
- 8.6.7 Chile Sales Analysis
- 8.6.8 Rest of Latin America Sales Analysis
8.7. Middle East & Africa Sales Analysis
- 8.7.1 Overview, Historic and Forecast Data Sales Analysis
- 8.7.2 Middle East & Africa By Segment Sales Analysis
- 8.7.3 Middle East & Africa By Country Sales Analysis
- 8.7.4 Saudi Arabia Sales Analysis
- 8.7.5 UAE Sales Analysis
- 8.7.6 Israel Sales Analysis
- 8.7.7 South Africa Sales Analysis
- 8.7.8 Rest Of Middle East And Africa Sales Analysis

9. COMPETITIVE LANDSCAPE OF THE SMALL MOLECULE INNOVATOR API CDMO COMPANIES

9.1. Small Molecule Innovator API CDMO Market Competition
9.2. Partnership/Collaboration/Agreement
9.3. Merger And Acquisitions
9.4. New Product Launch
9.5. Other Developments

10. COMPANY PROFILES OF SMALL MOLECULE INNOVATOR API CDMO INDUSTRY

10.1. Top Companies Market Share Analysis
10.2. Market Concentration Rate
10.3. Lonza Group Ltd.
- 10.3.1 Company Overview
- 10.3.2 Company Revenue
- 10.3.3 Products
- 10.3.4 Recent Developments
10.4. Novo Holdings (Catalent Inc.)
- 10.4.1 Company Overview
- 10.4.2 Company Revenue
- 10.4.3 Products
- 10.4.4 Recent Developments
10.5. Thermo Fisher Scientific Inc.
- 10.5.1 Company Overview
- 10.5.2 Company Revenue
- 10.5.3 Products
- 10.5.4 Recent Developments
10.6. Siegfried Holding AG
- 10.6.1 Company Overview
- 10.6.2 Company Revenue
- 10.6.3 Products
- 10.6.4 Recent Developments
10.7. Recipharm AB
- 10.7.1 Company Overview
- 10.7.2 Company Revenue
- 10.7.3 Products
- 10.7.4 Recent Developments
10.8. CordenPharma International
- 10.8.1 Company Overview
- 10.8.2 Company Revenue
- 10.8.3 Products
- 10.8.4 Recent Developments
10.9. Samsung Biologics
- 10.9.1 Company Overview
- 10.9.2 Company Revenue
- 10.9.3 Products
- 10.9.4 Recent Developments
10.10. LabCorp
- 10.10.1 Company Overview
- 10.10.2 Company Revenue
- 10.10.3 Products
- 10.10.4 Recent Developments
10.11. Ajinomoto Bio-Pharma Services
- 10.11.1 Company Overview
- 10.11.2 Company Revenue
- 10.11.3 Products
- 10.11.4 Recent Developments
10.12. Piramal Pharma Solutions
- 10.12.1 Company Overview
- 10.12.2 Company Revenue
- 10.12.3 Products
- 10.12.4 Recent Developments
10.13. Jubilant Life Sciences (Jubilant Biosys Ltd.)
- 10.13.1 Company Overview
- 10.13.2 Company Revenue
- 10.13.3 Products
- 10.13.4 Recent Developments
10.14. WuXi AppTec Co. Ltd.
- 10.14.1 Company Overview
- 10.14.2 Company Revenue
- 10.14.3 Products
- 10.14.4 Recent Developments

Note - In company profiling, financial details and recent developments are subject to availability or might not be covered in the case of private companies